Company intelligence / Profile preview

MitrAssist

Misgav, Karmiel, Israel

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Initial clinical results for SIKELIA™ polymeric heart valve (THV) for TAVI in severe symptomatic aortic stenosis showed favorable 1-year safety and performance: reduced mean pressure gradient, increased effective orifice area, improved NYHA class, 6-minute walk test, KCCQ score, and normal leaflet mobility without HALT or calcification in 12 patients (max 27 months follow-up).[2][3]

Therapeutic areas: Cardiovascular
Modalities: Medical Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on MitrAssist.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MitrAssist.

Explore the full profile